STOCK TITAN

XWELL Announces $1.4 Million Registered Direct Offering Priced At Premium to Market

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

XWELL, Inc. (Nasdaq: XWEL) has announced a registered direct offering of 652,705 shares of common stock at $2.18 per share, priced at a premium to market. The offering is expected to close around August 8, 2024, generating gross proceeds of approximately $1.4 million. XWELL plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement on Form S-3. A final prospectus supplement and accompanying base prospectus will be filed with the SEC, available at www.sec.gov.

XWELL, Inc. (Nasdaq: XWEL) ha annunciato un offerta diretta registrata di 652.705 azioni ordinarie a 2,18 $ per azione, fissata a un premio sul mercato. Si prevede che l'offerta si chiuda intorno al 8 agosto 2024, generando proventi lordi di circa 1,4 milioni di dollari. XWELL intende utilizzare i proventi netti per capitale circolante e scopi aziendali generali. L'offerta è realizzata ai sensi di un modulo di registrazione shelf precedentemente depositato e valido, in base al modulo S-3. Un supplemento al prospetto finale e il prospetto base saranno depositati presso la SEC, disponibili su www.sec.gov.

XWELL, Inc. (Nasdaq: XWEL) ha anunciado una oferta directa registrada de 652,705 acciones ordinarias a $2.18 por acción, a un precio superior al del mercado. Se espera que la oferta se cierre alrededor del 8 de agosto de 2024, generando ingresos brutos de aproximadamente $1.4 millones. XWELL planea utilizar los ingresos netos para capital de trabajo y fines corporativos generales. La oferta se realiza en virtud de un estado de registro en estantería presentado anteriormente y efectivo en el formulario S-3. Un suplemento del prospecto final y el prospecto base correspondiente se presentarán ante la SEC, disponibles en www.sec.gov.

XWELL, Inc. (Nasdaq: XWEL)는 등록 직접 공모로 652,705주 보통주를 주당 2.18달러에 발행한다고 발표했습니다. 이는 시장 가격보다 높은 프리미엄이 적용된 가격입니다. 이 공모는 2024년 8월 8일경에 마감될 것으로 예상되며, 총 약 140만 달러의 수익을 창출할 것입니다. XWELL은 순수익을 운영 자본 및 일반 기업 용도에 사용할 계획입니다. 이번 공모는 이전에 제출된 유효한 선반 등록명세서에 따라 이루어집니다. 최종 참석자 보충문서 및 기본 보충서가 SEC에 제출되며, www.sec.gov에서 확인할 수 있습니다.

XWELL, Inc. (Nasdaq: XWEL) a annoncé une offre directe enregistrée de 652 705 actions ordinaires à 2,18 $ par action, fixée à un prix supérieur au marché. L'offre devrait être clôturée autour du 8 août 2024, générant des produits bruts d'environ 1,4 million de dollars. XWELL prévoit d'utiliser les produits nets pour le fonds de roulement et des fins générales d'entreprise. L'offre est réalisée conformément à un état d'enregistrement de type étagère précédemment déposé et en vigueur sur le formulaire S-3. Un supplément de prospectus final et le prospectus de base correspondant seront déposés auprès de la SEC, disponibles sur www.sec.gov.

XWELL, Inc. (Nasdaq: XWEL) hat ein registriertes Direktangebot von 652.705 Stammaktien zu einem Preis von 2,18 $ pro Aktie bekannt gegeben, der über dem Marktpreis liegt. Die Emission wird voraussichtlich um den 8. August 2024 abgeschlossen und wird voraussichtlich Bruttoeinnahmen von etwa 1,4 Millionen Dollar generieren. XWELL plant, die Nettoprognosen für Betriebs- und allgemeine Unternehmenszwecke zu verwenden. Das Angebot erfolgt auf der Grundlage eines zuvor eingereichten und wirksamen Regalregistrierungsantrags nach Formular S-3. Ein endgültiger Prospektzusatz und der zugehörige Basisprospekt werden bei der SEC eingereicht und sind auf www.sec.gov verfügbar.

Positive
  • Offering priced at a premium to market, indicating investor confidence
  • Expected gross proceeds of $1.4 million to strengthen working capital
  • Utilization of existing shelf registration, streamlining the offering process
Negative
  • Potential dilution of existing shareholders' ownership
  • Relatively small offering size may not significantly impact company's financial position

XWELL's $1.4 million registered direct offering, priced at a premium to market, is a mixed signal for investors. While the premium pricing suggests confidence in the company's value, the small size of the offering raises questions about its impact on XWELL's financial position.

The 652,705 new shares at $2.18 per share represent a relatively small dilution for existing shareholders. However, the intended use for working capital and general corporate purposes doesn't indicate a specific growth strategy or investment plan, which may concern some investors looking for clear direction.

This capital raise, while positive for short-term liquidity, may not significantly alter XWELL's long-term prospects. Investors should closely monitor the company's subsequent financial reports to gauge the effectiveness of this capital injection.

The premium pricing of XWELL's offering at $2.18 per share suggests a positive market perception of the company's wellness solutions for travelers. This could indicate potential growth in the on-the-go wellness sector, aligning with increasing consumer focus on health and convenience.

However, the modest size of the $1.4 million offering may limit its impact on XWELL's market position. Competitors in the wellness space often secure larger funding rounds, potentially putting XWELL at a disadvantage in terms of scaling operations or marketing efforts.

Investors should consider how this capital infusion compares to industry trends and whether it's sufficient for XWELL to maintain or expand its market share in the competitive wellness solutions market.

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 652,705 shares of its common stock, par value $0.01 per share, at a purchase price of $2.18 per share in a registered direct offering priced at a premium to market. The closing of the offering is expected to occur on or about August 8, 2024, subject to the satisfaction of customary closing conditions.

The gross proceeds to the Company from the offering are expected to be approximately $1.4 million, before deducting other offering expenses payable by the Company. The Company intends to use the net proceeds of this offering for working capital and general corporate purposes.

The shares of common stock offered in the registered direct offering described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-273726) that was previously filed with the Securities and Exchange Commission (“SEC”) on August 4, 2023, and subsequently declared effective on September 29, 2023. The offering of the shares of common stock to be issued in the registered direct offering are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About XWELL, Inc.

XWELL, Inc. (Nasdaq: XWEL) is a leading global wellness holding company operating multiple brands: XpresSpa®, Treat™, Naples Wax Center®, XpresCheck® and HyperPointe™.

  • XpresSpa is a leading retailer of wellness services and related products, with 33 locations in 16 airports globally.
  • Naples Wax Center is a group of upscale skin care boutiques, with three locations currently operating.
  • XpresCheck is a provider of screening and diagnostic testing in partnership with the CDC and Concentric by Ginkgo, conducting biosurveillance monitoring in its airport locations to identify new SARS-CoV-2 variants of interest and concern as well as other pathogens entering the country from across the world.
  • HyperPointe is a leading digital healthcare and data analytics relationship company serving the global healthcare industry.

Forward-looking Statements

This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” or the negative of such terms, or other comparable terminology, and include such risks and uncertainties such as market and other conditions. Forward-looking statements relating to expectations about future results or events, including statements related to the timing and completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of proceeds the registered direct offering, the Company’s current plans and expectations relating to the business and operations and future store openings, including but not limited to, future openings of Naples Wax Center and XpresSpa stores, are based upon information available to XWELL as of the date of this press release, and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company’s Annual Report on Form 10-K, as amended, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other SEC filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.


FAQ

What is the price per share for XWELL's registered direct offering?

XWELL's registered direct offering is priced at $2.18 per share, which is at a premium to the market price.

How many shares is XWELL (XWEL) offering in its August 2024 registered direct offering?

XWELL is offering an aggregate of 652,705 shares of its common stock in the August 2024 registered direct offering.

What are the expected gross proceeds from XWELL's August 2024 offering?

The expected gross proceeds from XWELL's August 2024 offering are approximately $1.4 million, before deducting offering expenses.

When is the closing date for XWELL's (XWEL) registered direct offering?

The closing of XWELL's registered direct offering is expected to occur on or about August 8, 2024, subject to customary closing conditions.

How does XWELL plan to use the proceeds from its August 2024 offering?

XWELL intends to use the net proceeds from the August 2024 offering for working capital and general corporate purposes.

XWELL, Inc.

NASDAQ:XWEL

XWEL Rankings

XWEL Latest News

XWEL Stock Data

9.96M
5.26M
9.05%
14.94%
1.6%
Diagnostics & Research
Services-personal Services
Link
United States of America
NEW YORK